MTSL Issue 810

 Comments Off on MTSL Issue 810
Sep 062015
 
MTSL Issue 810

Issue No. 810 (dated 9/03/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ACAD #ANTH #INCY #OGXI #SGMO #MDCO

MTSL Issue 809

 Comments Off on MTSL Issue 809
Aug 232015
 
MTSL Issue 809

Issue No. 809 (dated 8/20/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ACAD #ANTH #NVAX #OGXI #ZIOP

MTSL Issue 808

 Comments Off on MTSL Issue 808
Aug 092015
 
MTSL Issue 808

Issue No. 808 (dated 8/6/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ALKS #ANTH #BMRN #INCY #ISIS #MDCO #NKTR #NVAX #PCRX #SGMO #ZIOP

MTSL Issue 807

 Comments Off on MTSL Issue 807
Jul 262015
 
MTSL Issue 807

Issue No. 807 (dated 7/23/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ANTH #BMRN #ISIS #MDCO #NKTR #NVAX

MoneyShow – Top Picks Mid-Year Winners: Jay Silverman (7-6-15)

 Comments Off on MoneyShow – Top Picks Mid-Year Winners: Jay Silverman (7-6-15)
Jul 062015
 
MoneyShow - Top Picks Mid-Year Winners: Jay Silverman (7-6-15)

In January, MoneyShow asked all of the nation’s leading advisors to select a favorite stock for 2015. In this special series of interviews we are talking with the five advisors who had the top performing stock picks as of mid-year. Here, we talk with Jay Silverman, editor of The Medical Technology Stock Letter, to discuss a top performing biotechnology company.

MTSL Issue 806

 Comments Off on MTSL Issue 806
Jul 022015
 
MTSL Issue 806

Issue No. 806 (dated 7/2/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ALKS, #ANTH, #BMRN, #ISIS, #MDCO

MoneyShow: Biotech Catalysts (6-22-15)

 Comments Off on MoneyShow: Biotech Catalysts (6-22-15)
Jun 302015
 
MoneyShow:  Biotech Catalysts (6-22-15)

Our guest today is Jay Silverman, a leading biotechnology sector analyst and editor of The Medical Technology Stock Letter. He updates us on the acquisition of one of his long-standing recommendations, the impact of this deal on the biotech space, and a trio of additional ideas for long-term investors to consider.

MTSL Issue 805

 Comments Off on MTSL Issue 805
Jun 122015
 
MTSL Issue 805

Issue No. 805 (dated 6/11/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ANTH, #CBMG, #IMGN, #INCY, #ISIS, #MDCO, #NKTR, #OGXI, #ZIOP

ANTHERA – TASTING CHABLIS – A Well-Designed Trial To Increase The Likelihood of Success

 Comments Off on ANTHERA – TASTING CHABLIS – A Well-Designed Trial To Increase The Likelihood of Success
Apr 202015
 
ANTHERA – TASTING CHABLIS – A Well-Designed Trial To Increase The Likelihood of Success

After the successful completion of two interim looks at the Phase III trials for blisibimod, we spoke with Anthera Chief Medical Officer Colin Hislop M.D. to further delve into the CHABLIS study design. After performing further due diligence, we remain confident in b-mod’s clinical potential and believe that the odds of success are much greater than they were in PEARL.

MoneyShow: A Trio of Biotech Favorites (4-6-15)

 Comments Off on MoneyShow: A Trio of Biotech Favorites (4-6-15)
Apr 062015
 
MoneyShow: A Trio of Biotech Favorites (4-6-15)

Our guest today is Jay Silverman, a leading biotechnology sector analyst and editor of The Medical Technology Stock Letter. He updates us on the acquisition of one of his long-standing recommendations, the impact of this deal on the biotech space, and a trio of additional ideas for long-term investors to consider.

Anthera Update (3-17-15)

 Comments Off on Anthera Update (3-17-15)
Mar 172015
 
Anthera Update (3-17-15)

      Special Update – Anthera (ANTH) – Raising TARGET PRICE to 25 IgAN Positive Interim Look Is Second Straight For B-Mod Update With Management Confirms Improving Fundamentals Stock Sell Off Unwarranted; $92m. mkt cap & 3 Phase IIIs Raising TARGET PRICE to 25 B-Mod IgAN Passes Futility Check – Anthera delivered another positive interim […]

Biotech Fund Managers – What The Pros Do Every Year

 Comments Off on Biotech Fund Managers – What The Pros Do Every Year
Aug 222014
 
Biotech Fund Managers - What The Pros Do Every Year

Biotech Fund Managers – What The Pros Do Every Year  August 21, 2014   The Medical Technology Stock Letter (“MTSL”) prides itself on identifying exciting small companies that will become leaders in their respective fields over time. We emphasize “over time” because that is the nature of drug development and compounded returns of successful biotech […]

A BRIEF IMMUNE-ONCOLOGY UPDATE

 Comments Off on A BRIEF IMMUNE-ONCOLOGY UPDATE
Jun 202014
 
A BRIEF IMMUNE-ONCOLOGY UPDATE

A BRIEF IMMUNE-ONCOLOGY UPDATE June 12, 2014 ASCO 2014 – Immune Oncology Rises to the Top – As many expected, immune oncology (I-O) was all the rage at the recently concluded American Society of Clinical Oncology (ASCO) meeting.  While it is widely acknowledged that before ASCO, Bristol was the leader in the space followed by […]